person · Reporting owner

Studer Jacqueline

Disclosed activity across 2 companies

Tapewire entity: 89266
SEC CIK: 0001526223

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IDEXX LABORATORIES INC /DEIDXX · Entity 3057	CVP, Gen. Counsel & Secretary	February 25, 2019	February 27, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IDEXX LABORATORIES INC /DE

Report date February 25, 2019 · Filed February 27, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,389	Ending reported balance After 2019-02-26 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2019-02-25 · Exercise / conversion · Acquired 1,156 · Balance 6,918 Row 2 · 2019-02-25 · Sale · Disposed 1,223 · Balance 5,695 F1: Represents the weighted average sales price of the shares sold ranging from a low of $211.00 to a high of $211.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Row 3 · 2019-02-25 · Sale · Disposed 472 · Balance 5,223 Row 4 · 2019-02-26 · Sale · Disposed 834 · Balance 4,389 F2: Represents the weighted average sales price of the shares sold ranging from a low of $208.00 to a high of $208.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.54 · Expires 2025-02-13	Direct	708	Reported balance After 2019-02-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-02-25 · Exercise / conversion · Disposed 1,156 · Balance 708 F4: Not applicable. F3: Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the weighted average sales price of the shares sold ranging from a low of $211.00 to a high of $211.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F2: Represents the weighted average sales price of the shares sold ranging from a low of $208.00 to a high of $208.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F4: Not applicable.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Akili, Inc.

Report date July 02, 2024 · Filed July 02, 2024

Section 16 reporting ended · disclosed 2024-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001SEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-07-02 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-07-02 · Other · Disposed 30,693 · Balance 92,869 F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time") with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person or her affiliates was converted into the Offer Price. Row 2 · 2024-07-02 · Disposition to issuer · Disposed 92,869 · Balance 0 F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F3: Reflects disposition of time-based Issuer RSUs pursuant to the terms of the Merger Agreement. Each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into the right to receive a cash payment without interest, less any applicable tax withholding, equal to the Offer Price, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40	Direct	0	Reported balance After 2024-07-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-07-02 · Disposition to issuer · Disposed 280,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Price was cancelled and converted into the right to receive an amount in cash, without any interest thereon, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Offer Price over the exercise price per Share underlying such Issuer Stock Option by (y) the number of Shares underlying such Issuer Stock Option immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time") with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person or her affiliates was converted into the Offer Price.

F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.

F3: Reflects disposition of time-based Issuer RSUs pursuant to the terms of the Merger Agreement. Each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into the right to receive a cash payment without interest, less any applicable tax withholding, equal to the Offer Price, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.

F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Price was cancelled and converted into the right to receive an amount in cash, without any interest thereon, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Offer Price over the exercise price per Share underlying such Issuer Stock Option by (y) the number of Shares underlying such Issuer Stock Option immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 02, 2024 Filed Jul 2, 2024 10:31 UTC	Akili, Inc. AKLI · Entity 89130	Disposition to issuerStock Option (Right to buy) · Derivative	280,500	Not disclosed Strike: $0.40	Not disclosed	Disclosure SEC source: 0001562180-24-005425 · primarydocument.xml · derivative · entry 3 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 280,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Price was cancelled and converted into the right to receive an amount in cash, without any interest thereon, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Offer Price over the exercise price per Share underlying such Issuer Stock Option by (y) the number of Shares underlying such Issuer Stock Option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Price was cancelled and converted into the right to receive an amount in cash, without any interest thereon, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Offer Price over the exercise price per Share underlying such Issuer Stock Option by (y) the number of Shares underlying such Issuer Stock Option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Price was cancelled and converted into the right to receive an amount in cash, without any interest thereon, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Offer Price over the exercise price per Share underlying such Issuer Stock Option by (y) the number of Shares underlying such Issuer Stock Option immediately prior to the Effective Time. Read SEC document
July 02, 2024 Filed Jul 2, 2024 10:31 UTC	Akili, Inc. AKLI · Entity 89130	Disposition to issuerCommon Stock, par value $0.0001	92,869	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-24-005425 · primarydocument.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F3 · price: Reflects disposition of time-based Issuer RSUs pursuant to the terms of the Merger Agreement. Each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into the right to receive a cash payment without interest, less any applicable tax withholding, equal to the Offer Price, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. Read SEC document
July 02, 2024 Filed Jul 2, 2024 10:31 UTC	Akili, Inc. AKLI · Entity 89130	OtherCommon Stock, par value $0.0001	30,693	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-24-005425 · primarydocument.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,869 F1 · price: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time") with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person or her affiliates was converted into the Offer Price. Read SEC document
June 07, 2024 Filed Jun 11, 2024 17:38 UTC	Akili, Inc. AKLI · Entity 89130	Tax withholdingCommon Stock	5,118	$0.42	$2,163.38	Disclosure SEC source: 0001562180-24-004957 · primarydocument.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,212 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
May 02, 2024 Filed May 6, 2024 17:32 UTC	Akili, Inc. AKLI · Entity 89130	Tax withholdingCommon Stock	1,840	$0.41	$752.19	Disclosure SEC source: 0001562180-24-003854 · primarydocument.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 413,330 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
March 10, 2024 Filed Mar 12, 2024 17:28 UTC	Akili, Inc. AKLI · Entity 89130	Tax withholdingCommon Stock	1,032	$0.34	$350.88	Disclosure SEC source: 0001562180-24-002614 · primarydocument.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,170 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
December 07, 2023 Filed Dec 8, 2023 17:33 UTC	Akili, Inc. AKLI · Entity 89130	GrantStock Option (Right to buy) · Derivative	280,500	$0.00 Strike: $0.40	$0.00	Disclosure SEC source: 0001562180-23-008254 · primarydocument.xml · derivative · entry 2 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,500 Underlying: Common Stock · 280,500 shares Expires 2033-12-07 F2 · derivative.exercise_date: The shares underlying this option shall vest in four equal semiannual installments following the grant date, subject to the reporting person's continued service on each such vesting date. Read SEC document
December 07, 2023 Filed Dec 8, 2023 17:33 UTC	Akili, Inc. AKLI · Entity 89130	GrantCommon Stock	69,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-23-008254 · primarydocument.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,202 F1 · price: Represents a grant of restricted stock units ("RSUs") under the Akili, Inc. 2022 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs underlying this grant shall vest in four equal semiannual installments following the grant date, subject to the reporting person's continued service on each such vesting date. Read SEC document
November 02, 2023 Filed Nov 6, 2023 17:20 UTC	Akili, Inc. AKLI · Entity 89130	Tax withholdingCommon Stock	1,840	$0.39	$720.91	Disclosure SEC source: 0001562180-23-007573 · primarydocument.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,452 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
September 11, 2023 Filed Sep 14, 2023 08:31 UTC	Akili, Inc. AKLI · Entity 89130	SaleCommon Stock	1,130	$1.05	$1,186.50	Disclosure SEC source: 0000899243-23-018942 · doc4.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,292 F1 · shares: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document
May 02, 2023 Filed May 4, 2023 16:20 UTC	Akili, Inc. AKLI · Entity 89130	Tax withholdingCommon Stock	1,840	$1.09	$2,005.60	Disclosure SEC source: 0000899243-23-012260 · doc4.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,422 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
March 10, 2023 Filed Mar 14, 2023 16:38 UTC	Akili, Inc. AKLI · Entity 89130	GrantStock Option (Right to Buy) · Derivative	117,000	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0000899243-23-008422 · doc4.xml · derivative · entry 2 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,000 Underlying: Common Stock · 117,000 shares Expires 2033-03-10 F2 · derivative.exercise_date: The shares underlying this option shall vest in eight equal semiannual installments following the grant date, subject to the reporting person's continued service on each such vesting date. Read SEC document
March 10, 2023 Filed Mar 14, 2023 16:38 UTC	Akili, Inc. AKLI · Entity 89130	GrantCommon Stock	29,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-008422 · doc4.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,262 F1 · price: Represents a grant of restricted stock units ("RSUs") under the Akili, Inc. 2022 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs underlying this grant shall vest in eight equal semiannual installments following the grant date, subject to the reporting person's continued service on each such vesting date. Read SEC document
November 02, 2022 Filed Nov 4, 2022 18:55 UTC	Akili, Inc. AKLI · Entity 89130	GrantStock Option (Right to Buy) · Derivative	152,729	$0.00 Strike: $2.30	$0.00	Disclosure SEC source: 0000899243-22-035239 · doc4.xml · derivative · entry 3 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,729 Underlying: Common Stock · 152,729 shares Expires 2032-11-02 F3 · derivative.exercise_date: 16.67% of the shares underlying this option shall vest and become exercisable on May 2, 2023, with an additional 16.67% vesting at the end of each six (6) month period thereafter, subject to the reporting person's continued service on each such vesting date. Read SEC document
November 02, 2022 Filed Nov 4, 2022 18:55 UTC	Akili, Inc. AKLI · Entity 89130	GrantCommon Stock	284,650	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-035239 · doc4.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,262 F2 · price: Represents a grant of RSUs under the Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs underlying this grant shall vest upon the Issuer's common stock achieving certain specified prices per share, subject to the reporting person's continued service at such time. Read SEC document
November 02, 2022 Filed Nov 4, 2022 18:55 UTC	Akili, Inc. AKLI · Entity 89130	GrantCommon Stock	37,612	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-035239 · doc4.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,612 F1 · price: Represents a grant of restricted stock units ("RSUs") under the Akili, Inc. 2022 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 16.67% of the RSUs underlying this grant shall vest on May 2, 2023, with an additional 16.67% vesting at the end of each six (6) month period thereafter, subject to the reporting person's continued service on each such vesting date. Read SEC document
February 26, 2019 Filed Feb 27, 2019 22:24 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	834	$208.06	$173,523.46	Disclosure SEC source: 0001567619-19-005515 · doc1.xml · nonDerivative · entry 4 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,389 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $208.00 to a high of $208.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:24 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative	1,156	Not disclosed Strike: $79.54	Not disclosed	Disclosure SEC source: 0001567619-19-005515 · doc1.xml · derivative · entry 5 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 708 Underlying: Common Stock · 1,156 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:24 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	472	$212.05	$100,088.64	Disclosure SEC source: 0001567619-19-005515 · doc1.xml · nonDerivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,223 Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:24 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,223	$211.70	$258,907.27	Disclosure SEC source: 0001567619-19-005515 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,695 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $211.00 to a high of $211.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
February 25, 2019 Filed Feb 27, 2019 22:24 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	1,156	$79.54	$91,948.24	Disclosure SEC source: 0001567619-19-005515 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	1,714	Not disclosed Strike: $178.26	Not disclosed	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 18 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,293 Underlying: Common Stock · 1,714 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F9 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2019. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	2,219	Not disclosed Strike: $141.60	Not disclosed	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 17 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,948 Underlying: Common Stock · 2,219 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F8 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2018. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative	1	Not disclosed Strike: $67.85	Not disclosed	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 16 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,474 Underlying: Common Stock · 1 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F7 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	4,700	Not disclosed Strike: $67.85	Not disclosed	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 15 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,927 Underlying: Common Stock · 4,700 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F7 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative	100	Not disclosed Strike: $79.54	Not disclosed	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 14 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,864 Underlying: Common Stock · 100 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 3,140 shares of Issuer common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	2,866	Not disclosed Strike: $79.54	Not disclosed	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · derivative · entry 13 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,866 Underlying: Common Stock · 2,866 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F5 · derivative.exercise_date: Grant of option to buy 7,165 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,714	$209.18	$358,533.49	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 12 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762 F4 · price: Represents the weighted average sales price of the shares sold ranging from a low of $209.10 to a high of $209.37 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	1,714	$178.26	$305,537.64	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 11 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,219	$208.95	$463,665.15	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 10 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762 F3 · price: Represents the weighted average sales price of the shares sold ranging from a low of $208.91 to a high of $209.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	2,219	$141.60	$314,210.40	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 9 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1	$208.90	$208.90	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 8 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762 Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	1	$67.85	$67.85	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 7 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	4,700	$208.54	$980,132.83	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 6 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $207.81 to a high of $208.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	4,700	$67.85	$318,895.00	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 5 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	100	$207.80	$20,780.00	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 4 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762 Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	100	$79.54	$7,954.00	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,866	$207.54	$594,795.88	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762 F1 · price: Represents the weighted average sales price of the shares sold ranging from a low of $207.08 to a high of $208.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
February 15, 2019 Filed Feb 20, 2019 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	2,866	$79.54	$227,961.64	Disclosure SEC source: 0001567619-19-005004 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:08 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	169	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004924 · doc1.xml · derivative · entry 9 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,591 Underlying: Common Stock · 169 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F6 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:08 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	212	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004924 · doc1.xml · derivative · entry 8 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,760 Underlying: Common Stock · 212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F6 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:08 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	405	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004924 · doc1.xml · derivative · entry 7 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,972 Underlying: Common Stock · 405 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. The number of RSUs have been adjusted to reflect the Stock Split. F6 · price: Not applicable. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. The number of RSUs have been adjusted to reflect the Stock Split. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. The number of RSUs have been adjusted to reflect the Stock Split. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:08 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	345	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-19-004924 · doc1.xml · derivative · entry 6 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,377 Underlying: Common Stock · 345 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F6 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five equal annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:08 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Tax withholdingCommon Stock	345	$206.94	$71,394.30	Disclosure SEC source: 0001567619-19-004924 · doc1.xml · nonDerivative · entry 5 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,762 Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:08 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	169	$0.00	$0.00	Disclosure SEC source: 0001567619-19-004924 · doc1.xml · nonDerivative · entry 4 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:08 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	212	$0.00	$0.00	Disclosure SEC source: 0001567619-19-004924 · doc1.xml · nonDerivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:08 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	405	$0.00	$0.00	Disclosure SEC source: 0001567619-19-004924 · doc1.xml · nonDerivative · entry 2 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2019 Filed Feb 19, 2019 23:08 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	345	$0.00	$0.00	Disclosure SEC source: 0001567619-19-004924 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 25 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2018. Read SEC document
November 06, 2018 Filed Nov 7, 2018 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	3,313	$201.27	$666,822.75	Disclosure SEC source: 0001567619-18-005303 · doc1.xml · nonDerivative · entry 1 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,951 F2 · price: Represents the weighted average sales price of the shares sold ranging from a low of $201.04 to a high of $201.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes Includes 25 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 28, 2018. Read SEC document
August 31, 2018 Filed Sep 4, 2018 21:05 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	1,129	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-18-002057 · doc1.xml · derivative · entry 3 Studer Jacqueline · CIK 0001526223 · CVP, Gen. Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,722 Underlying: Common Stock · 1,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These restricted stock units were granted to the reporting person on September 1, 2014. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F2 · price: Not applicable. F1 · derivative.exercise_date: These restricted stock units were granted to the reporting person on September 1, 2014. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F1 · derivative.expiration_date: These restricted stock units were granted to the reporting person on September 1, 2014. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in five equal annual installments, beginning on the first anniversary date of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.